1 October 2019 in Disease Models & Mechanisms
Owing to their high similarity to humans, non-human primates (NHPs) provide an exceedingly suitable model for the study of human disease. In this Review, we summarize the history of transgenic NHP models and the progress of CRISPR/Cas9-mediated genome editing in NHPs, from the first proof-of-principle green fluorescent protein-expressing monkeys to sophisticated NHP models of human neurodegenerative disease that accurately phenocopy several complex disease features. We discuss not only the breakthroughs and advantages, but also the potential shortcomings of the application of the CRISPR/Cas9 system to NHPs that have emerged from the expanded understanding of this technology in recent years. Although off-target and mosaic mutations are the main concerns in CRISPR/Cas9-mediated NHP modeling, recent progress in genome editing techniques make it likely that these technical limitations will be overcome soon, bringing excellent prospects to human disease studies.
22 July 2022 in Science Advances
We report the cloning of a 12-year-old transgenic green fluorescent protein (GFP) monkey by somatic cell nuclear transfer (SCNT) and base editing of the embryos, accompanied with safety evaluation of adenine base editors (ABEs). We first show the ability of ABEmax to silence GFP through A-to-G editing of the GFP sequence in 293T cells. Subsequently, using donor cells from a monkey expressing GFP, we have successfully generated 207 ABEmax-edited (SCNT-ABE) and 87 wild-type (SCNT) embryos for embryo transfer, genotyping, and genome and transcriptome analysis. SCNT-ABE and SCNT embryos are compared for off-target analysis without the interference of genetic variants using a new method named as OA-SCNT. ABEmax does not induce obvious off-target DNA mutations but induces widespread off-target RNA mutations, 35% of which are exonic, in edited monkey embryos. These results provide important references for clinical application of ABE.
3 November 2026 in npj Aging
Nuclear lamina dysfunction is a hallmark of aging, yet its upstream drivers remain unclear. Here, we identify β-catenin loss as a central driver of nuclear lamina deterioration and cellular senescence. Using primary fibroblasts derived from base-edited non-human primate models of Hutchinson-Gilford progeria syndrome (HGPS) and from physiologically aged non-human primates, together with skin tissue validation from HGPS model animals, we show that β-catenin depletion is sufficient to induce nuclear abnormalities and proliferative arrest. Mechanistically, β-catenin is suppressed by a dual-layer regulatory program involving enhancer dysfunction that reduces CTNNB1 transcription and β-TrCP-mediated proteasomal degradation that limits protein abundance. Notably, β-TrCP undergoes subcellular redistribution in HGPS and physiologically aged non-human primate fibroblasts. Restoration of β-catenin activity via WNT3A stimulation, small-molecule activation, or CTNNB1 overexpression rescues nuclear architecture and reinstates proliferative capacity. Together, these findings link chromatin regulation and proteostasis to nuclear lamina integrity during aging.